Syncona Shs GBP (GB:SYNC) has released an update.
Syncona Limited has launched Slingshot, a new portfolio company aimed at accelerating early-stage scientific programs into promising biotech assets. With an initial £12.5 million commitment, Slingshot will develop its first program, Apini, targeting inflammatory diseases, and will leverage Syncona’s expertise to bridge the gap between academic innovation and clinical development. This initiative reflects Syncona’s strategy to efficiently translate cutting-edge science into high-potential biotech ventures.
For further insights into GB:SYNC stock, check out TipRanks’ Stock Analysis page.
